Marked aortic valve stenosis progression after receiving long-term aggressive cholesterol-lowering therapy using low-density lipoprotein apheresis in a patient with familial hypercholesterolemia

Circulation Journal

Volumn 73, Issue 5, 2009, Pages 963-966

  Tsuchida, Masayuki ^a   Kawashiri, Masa Aki ^a   Tada, Hayato ^a   Takata, Mutsuko ^a   Nohara, Atsushi ^a   Ino, Hidekazu ^a   Inazu, Akihiro ^a   Kobayashi, Junji ^a   Koizumi, Junji ^b   Mabuchi, Hiroshi ^a   Yamagishi, Masakazu ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b KANAZAWA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Aortic valve stenosis; Coronary artery disease; Familial hypercholesterolemia; Low density lipoprotein apheresis; Saphenous vein graft

Indexed keywords

ATORVASTATIN; COLESTILAN; COLESTYRAMINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PITAVASTATIN; PRAVASTATIN;

ADULT; AGED; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; AORTA VALVE REPLACEMENT; AORTA VALVE STENOSIS; APHERESIS; ARTICLE; CASE REPORT; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BYPASS SURGERY; DISEASE COURSE; DRUG WITHDRAWAL; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HUMAN; LEG PAIN; LONG TERM CARE; SAPHENOUS VEIN GRAFT; SECONDARY PREVENTION; UNSPECIFIED SIDE EFFECT;

ANGINA PECTORIS; ANTICHOLESTEREMIC AGENTS; AORTIC VALVE STENOSIS; BLOOD COMPONENT REMOVAL; CHOLESTEROL; CHOLESTYRAMINE; CORONARY ANGIOGRAPHY; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; DISEASE PROGRESSION; ECHOCARDIOGRAPHY; FEMALE; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEINS, LDL; MIDDLE AGED; SECONDARY PREVENTION;

EID: 65649084075     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-08-0164     Document Type: Article

References (17)

1. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle I, editors. The metabolic basis of inherited disease, 8th edn. New York: McGraw-Hill; 2001; 2863-2913.
2. Mabuchi H, Miyamoto S, Ueda K, Oota M, Takegoshi T, Wakasugi T, et al. Causes of death in patients with familial hypercholesterolemia. Atherosclerosis 1986; 61: 1-6. (Pubitemid 16098884)
3. Rallidis L, Naoumova RP, Thompson GR, Nihoyannopoulos P. Extent and severity of atherosclerotic involvement of the aortic valve and root in familial hypercholesterolaemia. Heart 1998; 80: 583-590. (Pubitemid 28561693)
4. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-1307.
5. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
6. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-1009.
7. Kawashiri M, Higashikata T, Nohara A, Kobayashi J, Inazu A, Koizumi J, et al. Efficacy of Colestimide coadministered with atorvastatin in Japanese patients with heterozygous familial hypercholesterolemia (FH). Circ J 2005; 69: 515-520. (Pubitemid 40745722)
8. Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, et al; Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression (SALTIRE) Investigators. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005; 352: 2389-2397.
9. Moura LM, Ramos SF, Zamorano JL, Barros IM, Azevedo LF, Rocha-Gonçalves F, et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol 2007; 49: 554-561. (Pubitemid 46177435)
10. Yu W, Nohara A, Higashikata T, Lu H, Inazu A, Mabuchi H. Molecular genetic analysis of familial hypercholesterolemia: Spectrum and regional difference of LDL receptor gene mutations in Japanese population. Atherosclerosis 2002; 165: 335-342. (Pubitemid 35333360)
11. Campeau L, Enjalbert M, Lespérance J, Vaislic C, Grondin CM, Bourassa MG. Atherosclerosis and late closure of aortocoronary saphenous vein grafts: Sequential angiographic studies at 2 weeks, 1 year, 5 to 7 years, and 10 to 12 years after surgery. Circulation 1983; 68: II-1-II-7.
12. Campeau L, Enjalbert M, Lespérance J, Bourassa MG, Kwiterovich P Jr, Wacholder S, et al. The relation of risk factors to the development of atherosclerosis in saphenous-vein bypass grafts and the progression of disease in the native circulation: A study 10 years after aortocoronary bypass surgery. N Engl J Med 1984; 311: 1329-1332. (Pubitemid 15129601)
13. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997; 336: 153-162.
14. Hata M, Sezai A, Niino T, Yoda M, Wakui S, Chiku M, et al. What is the optimal management for preventing saphenous vein graft diseases?: Early results of intravascular angioscopic assessment. Circ J 2007; 71: 286-287. (Pubitemid 46182707)
15. Mabuchi H, Koizumi J, Shimizu M, Kajinami K, Miyamoto S, Ueda K, et al. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Am J Cardiol 1998; 82: 1489-1495. (Pubitemid 29006472)
16. Stewart BF, Siscovick D, Lind BK, Gardin JM, Gottdiener JS, Smith VE, et al. Clinical factors associated with calcific aortic valve disease: Cardiovascular Health Study. J Am Coll Cardiol 1997; 29: 630-634.
17. Nozue T, Kawashiri MA, Higashikata T, Nohara A, Inazu A, Kobayashi J, et al. Cholesterol-years score is associated with development of senile degenerative aortic stenosis in heterozygous familial hypercholesterolemia. J Atheroscler Thromb 2006; 13: 323-328.